<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019695</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066964</org_study_id>
    <secondary_id>NCI-99-C-0052</secondary_id>
    <nct_id>NCT00019695</nct_id>
    <nct_alias>NCT00001802</nct_alias>
  </id_info>
  <brief_title>Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the&#xD;
      growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone&#xD;
      metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is&#xD;
      more effective with or without alendronate sodium.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without&#xD;
      alendronate sodium in treating patients who have metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether there is any evidence that ketoconazole plus alendronate&#xD;
      sodium produces acceptable disease responses as compared with ketoconazole alone in patients&#xD;
      with androgen-independent metastatic adenocarcinoma of the prostate.&#xD;
&#xD;
      II. Characterize the pharmacokinetics/pharmacodynamics and assess the bone marrow&#xD;
      concentrations of both agents.&#xD;
&#xD;
      III. Assess matrix metalloproteinase (MMP) inhibition potential of alendronate sodium by&#xD;
      monitoring markers of angiogenesis, MMP breakdown, and changes in hydroxyproline.&#xD;
&#xD;
      PROTOCOL OUTLINE: This is a randomized, open-label study. Patients are randomized to one of&#xD;
      two treatment arms.&#xD;
&#xD;
      Arm I: Patients receive a single oral dose of ketoconazole on day 1. Patients begin taking&#xD;
      ketoconazole 3 times per day on day 8.&#xD;
&#xD;
      Arm II: Patients receive a single oral dose of alendronate sodium on day 1 and a single oral&#xD;
      dose of ketoconazole on day 3. Patients begin taking alendronate sodium once every morning&#xD;
      and ketoconazole 3 times per day on day 8.&#xD;
&#xD;
      Treatment continues on both arms in the absence of unacceptable toxicity or disease&#xD;
      progression. Patients who experience a clinical complete remission (CR) receive treatment for&#xD;
      an additional 60 days beyond documentation of a clinical CR.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A total of 72 patients (36 per arm) will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Histologically confirmed adenocarcinoma of the prostate&#xD;
        Androgen independent with at least 1 bone lesion that is felt to be associated with&#xD;
        metastatic disease Refractory disease must be demonstrated after the withdrawal of&#xD;
        flutamide, nilutamide, bicalutamide, or any other antiandrogen Clinically progressive&#xD;
        disease for at least 1 month documented by rising PSA levels, at least 1 new metastatic&#xD;
        deposit on Tc-99 bone scintigraphy, increasing measurable disease, or new areas of&#xD;
        malignant disease Patients with PSA-negative disease (i.e., PSA less than 10 ng/mL) must&#xD;
        have positive CT scans of soft tissue disease that can be used for disease staging, bone&#xD;
        scan, or some other form of documentable disease progression (i.e., rising carcinoembryonic&#xD;
        antigen, prostatic acid phosphatase) Testosterone in the range expected for castrated males&#xD;
        No brain metastases or primary CNS malignancies No unresolved acute local complications&#xD;
        that require urgent local medical therapy (such as severe bone pain, spinal cord&#xD;
        compression, or urinary flow obstruction) --Prior/Concurrent Therapy-- Biologic therapy:&#xD;
        Not specified Chemotherapy: No prior ketoconazole for prostate cancer Endocrine therapy:&#xD;
        See Disease Characteristics Treatment with LHRH agonist must continue for those patients&#xD;
        who have not undergone surgical castration If LHRH agonist has been discontinued, it must&#xD;
        be reinstituted with documented disease progression At least 4 weeks since prior hormonal&#xD;
        therapy other than LHRH agonist and recovered Radiotherapy: Prior radiotherapy to the&#xD;
        prostate allowed At least 4 weeks since prior radiotherapy and recovered Surgery: Prior&#xD;
        radical prostatectomy allowed At least 4 weeks since prior surgery and recovered Other: At&#xD;
        least 4 weeks since other prior anti-cancer therapy and recovered No prior transfusion with&#xD;
        strontium chloride Sr 89 and/or samarium Sm 153 lexidronam pentasodium No concurrent&#xD;
        phenytoin, theophylline, cisapride, triazolam, astemizole, loratadine, rifampin, isoniazid,&#xD;
        erythromycin, terfenadine, midazolam, alprazolam, atorvastatin calcium, cerivastatin&#xD;
        sodium, dofetilide, lovastatin, pimozide, simvastatin, or sirolimus No concurrent drugs&#xD;
        that decrease gastric acid output or increase gastric pH (e.g., antacids, cimetidine,&#xD;
        ranitidine, or antimuscarinics) No concurrent warfarin --Patient Characteristics-- Age: 18&#xD;
        and over Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic:&#xD;
        Granulocyte count at least 1,000/mm3 Hemoglobin at least 8.0 g/dL (pretreatment transfusion&#xD;
        allowed, provided hemoglobin is maintained for more than 30 days without additional&#xD;
        transfusions and/or an active source of bleeding is identified and treated) Platelet count&#xD;
        at least 75,000/mm3 Hepatic: Acute care panel (i.e., electrolytes, BUN) and urinalysis&#xD;
        normal Bilirubin no greater than 1.2 mg/dL ALT less than 2.5 times upper limit of normal&#xD;
        AST less than 2.5 times normal Renal: Creatinine no greater than 1.5 mg/dL and no&#xD;
        proteinuria present OR Creatinine clearance greater than 40 mL/min and proteinuria less&#xD;
        than 500 mg/day (proteinuria not an exclusion for patients with stents in place)&#xD;
        Cardiovascular: No history of unstable or newly diagnosed angina pectoris No myocardial&#xD;
        infarction within the past 6 months No New York Heart Association class II-IV congestive&#xD;
        heart failure Pulmonary: No chronic obstructive lung disease requiring oxygen therapy&#xD;
        Neurologic: No uncontrolled seizure activity No history of seizures within the past 10&#xD;
        years Other: No other prior malignancies within the past 2 years except nonmelanoma skin&#xD;
        cancer or carcinoma in situ of the bladder No other life-threatening illnesses No untreated&#xD;
        infection HIV negative Willingness to travel from home to NIH for follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>William D. Figg</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2004</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>cancer</keyword>
  <keyword>cellular diagnosis, prostate cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>male reproductive cancer</keyword>
  <keyword>metastatic cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>site, metastatic cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>stage, prostate cancer</keyword>
  <keyword>unclassified/other cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

